1. Lublin, FD, Coetzee, T, Cohen, JA, et al. The 2013 clinical course descriptors for multiple sclerosis: A clarification. Neurology 2020; 94: 1088–1092.
Google Scholar | Crossref | Medline2. Kassa, RM, Sechi, E, Flanagan, EP, et al. Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Mult Scler 2020: 1352458520940983. DOI: 27(6): 895–902. 10.1177/1352458520940983
Google Scholar | SAGE Journals3. Nayak, S, Sechi, E, Flanagan, EP, et al. Inflammatory activity following motor progression due to critical CNS demyelinating lesions. Mult Scler 2020: 1352458520948745. DOI: 27(7): 1037–1045. 10.1177/1352458520948745
Google Scholar | SAGE Journals4. Keegan, BM, Kaufmann, TJ, Weinshenker, BG, et al. Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion. Neurology 2016; 87: 1713–1719.
Google Scholar | Crossref | Medline5. Keegan, BM, Kaufmann, TJ, Weinshenker, BG, et al. Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. Mult Scler 2018; 24: 1445–1452.
Google Scholar | SAGE Journals | ISI6. Sechi, E, Keegan, BM, Kaufmann, TJ, et al. Unilateral motor progression in MS: Association with a critical corticospinal tract lesion. Neurology 2019; 93: e628–e634.
Google Scholar | Crossref | Medline7. Thompson, AJ, Banwell, BL, Barkhof, F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162–173.
Google Scholar | Crossref | Medline | ISI8. Lebrun-Frenay, C, Kantarci, O, Siva, A, et al. Radiologically isolated syndrome: 10-year risk estimate of a clinical event. Ann Neurol 2020; 88: 407–417.
Google Scholar | Crossref | Medline9. Filippi, M, Rocca, MA, Ciccarelli, O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016; 15: 292–303.
Google Scholar | Crossref | Medline | ISI10. Tintore, M, Rovira, A, Rio, J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70: 1079–1083.
Google Scholar | Crossref | Medline | ISI11. Annunziata, P, Giorgio, A, De Santi, L, et al. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. J Neurol Sci 2006; 244: 97–102.
Google Scholar | Crossref | Medline | ISI12. Lechner-Scott, J, Spencer, B, de Malmanche, T, et al. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Mult Scler 2012; 18: 974–982.
Google Scholar | SAGE Journals | ISI13. Link, H, Huang, YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness. J Neuroimmunol 2006; 180: 17–28.
Google Scholar | Crossref | Medline | ISI14. Huttner, HB, Schellinger, PD, Struffert, T, et al. MRI Criteria in MS patients with negative and positive oligoclonal bands: Equal fulfillment of Barkhof's criteria but different lesion patterns. J Neurol 2009; 256: 1121–1125.
Google Scholar | Crossref | Medline | ISI15. Abdelhak, A, Hottenrott, T, Mayer, C, et al. CSF Profile in primary progressive multiple sclerosis: Re-exploring the basics. PLoS One 2017; 12: e0182647.
Google Scholar | Crossref | Medline16. Wolinsky, JS, Narayana, PA, O'Connor, P, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14–24.
Google Scholar | Crossref | Medline | ISI17. Lourenco, P, Shirani, A, Saeedi, J, et al. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: Associations with disease course and progression. Mult Scler 2013; 19: 577–584.
Google Scholar | SAGE Journals | ISI18. Imrell, K, Landtblom, AM, Hillert, J, et al. Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct. Neurology 2006; 67: 1062–1064.
Google Scholar | Crossref | Medline | ISI19. Dobson, R, Ramagopalan, S, Davis, A, et al. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013; 84: 909–914.
Google Scholar | Crossref | Medline | ISI20. Negrotto, L, Marrodan, M, Fiol, MP, et al. Absence of latitudinal gradient in oligoclonal bands prevalence in Argentina. Mult Scler Relat Disord 2020; 46: 102582.
Google Scholar | Crossref | Medline21. Schwenkenbecher, P, Wurster, U, Konen, FF, et al. Impact of the McDonald criteria 2017 on early diagnosis of relapsing-remitting multiple sclerosis. Front Neurol 2019; 10: 188.
Google Scholar | Crossref | Medline22. Disanto, G, Morahan, JM, Barnett, MH, et al. The evidence for a role of B cells in multiple sclerosis. Neurology 2012; 78: 823–832.
Google Scholar | Crossref | Medline | ISI23. Dubey, D, Pittock, SJ, Krecke, KN, et al. Clinical, radiologic, and prognostic features of myelitis associated With myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019; 76: 301–309.
Google Scholar | Crossref | Medline24. Lopez-Chiriboga, AS, Sechi, E, Buciuc, M, et al. Long-term outcomes in patients With myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder. JAMA Neurol 2020; 77(12): 1575–1577. 10.1001/jamaneurol.2020.3115
Google Scholar | Crossref | Medline